CN1270750C - Medicine for treating chronic nephritis, and its prepn. method - Google Patents
Medicine for treating chronic nephritis, and its prepn. method Download PDFInfo
- Publication number
- CN1270750C CN1270750C CN 200410006354 CN200410006354A CN1270750C CN 1270750 C CN1270750 C CN 1270750C CN 200410006354 CN200410006354 CN 200410006354 CN 200410006354 A CN200410006354 A CN 200410006354A CN 1270750 C CN1270750 C CN 1270750C
- Authority
- CN
- China
- Prior art keywords
- weight portion
- weight portions
- medicine
- filtrate
- carapax
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 206010018367 Glomerulonephritis chronic Diseases 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims description 28
- 238000000034 method Methods 0.000 title abstract description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 17
- 235000008434 ginseng Nutrition 0.000 claims abstract description 17
- 239000000706 filtrate Substances 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 241000208340 Araliaceae Species 0.000 claims description 16
- 210000000582 semen Anatomy 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 241000222640 Polyporus Species 0.000 claims description 9
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 9
- 238000001556 precipitation Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- -1 it is electuary Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 23
- 102000004169 proteins and genes Human genes 0.000 abstract description 12
- 108090000623 proteins and genes Proteins 0.000 abstract description 12
- 102000009027 Albumins Human genes 0.000 abstract description 9
- 108010088751 Albumins Proteins 0.000 abstract description 9
- 210000000952 spleen Anatomy 0.000 abstract description 9
- 210000003734 kidney Anatomy 0.000 abstract description 8
- 208000004880 Polyuria Diseases 0.000 abstract description 6
- 230000035619 diuresis Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 4
- 210000002784 stomach Anatomy 0.000 abstract description 3
- 238000005728 strengthening Methods 0.000 abstract description 2
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 241000209020 Cornus Species 0.000 abstract 1
- 235000003805 Musa ABB Group Nutrition 0.000 abstract 1
- 240000008790 Musa x paradisiaca Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 235000001188 Peltandra virginica Nutrition 0.000 abstract 1
- 235000015266 Plantago major Nutrition 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241000207929 Scutellaria Species 0.000 abstract 1
- 241000270708 Testudinidae Species 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 210000002700 urine Anatomy 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 8
- 102000007562 Serum Albumin Human genes 0.000 description 7
- 108010071390 Serum Albumin Proteins 0.000 description 7
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 7
- 229960004397 cyclophosphamide Drugs 0.000 description 7
- 201000008383 nephritis Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 230000003907 kidney function Effects 0.000 description 5
- 238000012353 t test Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241001489978 Eupolyphaga Species 0.000 description 1
- 241001251068 Formica fusca Species 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a medicine for treating chronic nephritis, which is prepared from ginseng, white atractylodes rhizome, cornus pulp, tortoise plastron, scutellaria, tuckahoe, alismatis, bupleurum root, periostracum cicadae, agaric, cassia twig, plantain seed, yam and ootheca mantidis. The medicine has the effects of strengthening spleens, nourishing stomachs, clearing away heat, promoting diuresis, expelling wind and dissipating evil and can be used for treating chronic nephritis. The medicine can improve clinical symptoms, reduce urinary proteins obviously, increase albumin, improve and protect the functions of kidneys. The medicine has no side or toxic effect. The present invention also discloses a method for preparing the medicine.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of chronic nephritis, specifically, is that a kind of to contain by Chinese crude drug be the medicine that feedstock production becomes effective ingredient.The invention still further relates to the preparation method of this medicine.
Background technology
Chronic nephritis full name chronic glomerulonephritis is caused by multiple reason, is primary in the immune inflammation disease of glomerule, is the intractable persistent ailment that present modern medicine circle is generally acknowledged.Existing document has also been reported the Chinese medicine of some treatment nephritis, discloses the Yichanmanshenkang medicine for curing nephroses of oral administration for treating chronicity nephritis as CN 1268355A, and this medicine is to be made by insect medicines such as Formica fusca, Eupolyphaga Seu Steleophagas, but curative effect and imprecise; CN 1088442A discloses a kind of medicine for the treatment of nephritis, and it is to be made by Radix Ginseng, Ramulus Cinnamomi, Radix Bupleuri etc., but same curative effect is also imprecise.So present still Chinese medicine of the treatment nephritis of a kind of determined curative effect of demand.The inventor has accumulated secular clinical experience, thinks that the pathogenic characteristic of chronic nephritis is a deficiency in origin and excess in superficiality, and deficiency in origin mainly shows as in various degree deficient, wherein important and common with spleen kidney qi Yin bivacuity of internal organs such as lung, spleen, liver, kidney.Mark is real mainly to be by due to many risk factors and the pathological product, as ailment said due to cold or exposure, damp and hot, blood stasis and turbid damp etc., wherein connects with damp and hot stream and had the greatest impact by ailment said due to cold or exposure repeatedly.Based on above understanding, in conjunction with clinical application experience for many years, having founded with nourishing spleen and kidney, clearing away heat-damp and promoting diuresis, the diffusing heresy of dispeling the wind is rule treatment chronic nephritis.Select the Chinese crude drug prescription to be prepared into medicine with this rule,, thereby finished the present invention through pharmacology and clinical experiment checking determined curative effect.
Summary of the invention
Goal of the invention of the present invention provides a kind of medicine for the treatment of chronic nephritis.
Another object of the present invention provides the preparation method of this medicine.
Medicine of the present invention is made up of effective ingredient and/or acceptable accessories, wherein prepares raw materials of effective components to be: Radix Ginseng, the Rhizoma Atractylodis Macrocephalae, Fructus Corni, Carapax et Plastrum Testudinis, Carapax Trionycis, Radix Scutellariae, Poria, Rhizoma Alismatis, Radix Bupleuri, Periostracum Cicadae, Polyporus, Ramulus Cinnamomi, Semen Plantaginis, Rhizoma Dioscoreae, Ootheca Mantidis.
Radix Ginseng, the strong Pi QI invigorating of the Rhizoma Atractylodis Macrocephalae; Fructus Corni, Carapax et Plastrum Testudinis, Rhizoma Dioscoreae, Ootheca Mantidis, Carapax Trionycis nourishing kidney replenishing essence; Radix Scutellariae, Poria, Semen Plantaginis, Rhizoma Alismatis clearing away heat-damp and promoting diuresis; Radix Bupleuri, Periostracum Cicadae, Ramulus Cinnamomi dispel the wind and remove heresy; Modern medicine study shows that Radix Ginseng, the Rhizoma Atractylodis Macrocephalae, Poria, Polyporus have the adjustment immunologic function, and renal function protecting reduces effects such as urine protein; Fructus Corni, Carapax et Plastrum Testudinis, Rhizoma Dioscoreae, Ootheca Mantidis, Carapax Trionycis also have renal function protecting, suppress the immunologic injury effect, and Carapax et Plastrum Testudinis, Carapax Trionycis be rich in aminoacid, protein, phospholipid, and liver detoxification is arranged, and the strengthening by means of tonics effect can promote plasma albumin synthetic.Heat-clearing and diuresis-promoting drugs such as Radix Scutellariae, Semen Plantaginis, Rhizoma Alismatis can be removed immune complex in the blood, suppress antigen antibody reaction, renal function protecting; The medical instruments that dispel the wind such as Radix Bupleuri, Periostracum Cicadae, Ramulus Cinnamomi have tangible antiallergic, antiallergic action effect.All medicines share has spleen invigorating taste stomach, clearing away heat-damp and promoting diuresis, the evil effect of loosing of dispeling the wind, and is used for the treatment of chronic nephritis, can improve clinical symptoms, can reduce urine protein significantly again, and raising albumin improves and renal function protecting.
In order to obtain better therapeutic, the consumption of raw material is:
Radix Ginseng 5-10 weight portion, Rhizoma Atractylodis Macrocephalae 5-10 weight portion, Fructus Corni 10-15 weight portion, Carapax et Plastrum Testudinis 10-15 weight portion, Carapax Trionycis 10-15 weight portion, Radix Scutellariae 3-9 weight portion, Poria 10-15 weight portion, Rhizoma Alismatis 25-30 weight portion, Radix Bupleuri 5-10 weight portion, Periostracum Cicadae 10-15 weight portion, Polyporus 10-15 weight portion, Ramulus Cinnamomi 1-5 weight portion, Semen Plantaginis 10-15 weight portion, Rhizoma Dioscoreae 15-20 weight portion and Ootheca Mantidis 25-30 weight portion.
In order to obtain best curative effect, the consumption of raw material is:
Radix Ginseng 9 weight portions, the Rhizoma Atractylodis Macrocephalae 9 weight portions, Fructus Corni 15 weight portions, Carapax et Plastrum Testudinis 15 weight portions, Carapax Trionycis 15 weight portions, Radix Scutellariae 6 weight portions, Poria 15 weight portions, Rhizoma Alismatis 30 weight portions, Radix Bupleuri 10 weight portions, Periostracum Cicadae 15 weight portions, Polyporus 15 weight portions, Ramulus Cinnamomi 3 weight portions, Semen Plantaginis 15 weight portions, Rhizoma Dioscoreae 20 weight portions and Ootheca Mantidis 30 weight portions.
The preparation method of effective ingredient can adopt the routine fashion of pharmaceutical field, as decoction and alcohol sedimentation technique or ethanol extract from water precipitation, and perhaps convection drying, pulverize.
The preferred for preparation method is: Carapax Trionycis and Carapax et Plastrum Testudinis are decocted with water 2-3 time, and each 20-24 hour, collecting decoction filtered, and filtrate is left standstill; Radix Ginseng is decocted with water 2-3 time, and each 0.5-1.5 hour, collecting decoction filtered, and filtrate is left standstill; All the other medicines decoct with water 2-3 time, wherein Semen Plantaginis decocted a drug wrapped, and each 0.5-1.5 hour, merge decoction, filter, filtrate is left standstill; Merge above-mentioned three kinds of filtrates, filter, it is 90-95 ℃ of survey 1.08 that filtrate is concentrated into relative density, room temperature to be chilled to adds equivalent ethanol and makes precipitation, gets supernatant concentration to relative density 60-65 ℃ of survey 1.20, add water, stir, leave standstill, get supernatant concentration to the relative density 60-65 ℃ of thick paste of surveying 1.38-1.40.
More preferably preparation method is: take by weighing raw material, Carapax Trionycis and Carapax et Plastrum Testudinis are decocted with water 3 times, each 24 hours, collecting decoction filtered, and filtrate is left standstill; Radix Ginseng is decocted with water twice, and each 1.5 hours, collecting decoction filtered, and filtrate is left standstill; All the other medicines decoct with water twice, wherein Semen Plantaginis are decocted a drug wrapped, and each 1.5 hours, merge decoction, filter, filtrate is left standstill; Merge above-mentioned three kinds of filtrates, filter, it is 90-95 ℃ of survey 1.08 that filtrate is concentrated into relative density, room temperature to be chilled to adds equivalent ethanol and makes precipitation, gets supernatant concentration to relative density 60-65 ℃ of survey 1.20, add 1 times of amount of water, stir, left standstill 8 hours, get supernatant concentration to the relative density 60-65 ℃ of thick paste of surveying 1.38-1.40.
Medicine of the present invention can be with above-mentioned effective ingredient convection drying, and pulverize is made powder; Perhaps above-mentioned effective ingredient and pharmaceutically acceptable conventional adjuvant are made various dosage forms, preferred electuary, granule, oral liquid, tablet or capsule.Preparation is during granule, preferably gets 1 part of the thick paste of effective ingredient, and with 3 parts of sucrose, 1.25 parts in dextrin and ethanol are made granule, drying, granulate, packing.
Medicine of the present invention has spleen invigorating taste stomach, clearing away heat-damp and promoting diuresis, the evil effect of loosing of dispeling the wind, and can be used for treating chronic nephritis, can improve clinical symptoms, can reduce urine protein significantly again, and raising albumin improves and renal function protecting, and without any side effects.
Embodiment 1:
1) takes by weighing following raw materials according: Radix Ginseng 9g, Rhizoma Atractylodis Macrocephalae 9g, Fructus Corni 15g, Carapax et Plastrum Testudinis 15g, Carapax Trionycis 15g, Radix Scutellariae 6g, Poria 15g, Rhizoma Alismatis 30g, Radix Bupleuri 10g, Periostracum Cicadae 15g, Polyporus 15g, Ramulus Cinnamomi 3g, Semen Plantaginis 15g, Rhizoma Dioscoreae 20g, Ootheca Mantidis 30g;
2) Carapax Trionycis and Carapax et Plastrum Testudinis are decocted with water 3 times, each 24 hours, collecting decoction filtered, and filtrate is left standstill;
3) Radix Ginseng is decocted with water twice, each 1.5 hours, collecting decoction filtered, and filtrate is left standstill;
4) all the other medicines decoct with water twice, wherein Semen Plantaginis are decocted a drug wrapped, and each 1.5 hours, merge decoction, filter, filtrate is left standstill; Merge above-mentioned three kinds of filtrates, filter, it is 90-95 ℃ of survey 1.08 that filtrate is concentrated into relative density, room temperature to be chilled to adds equivalent ethanol and makes precipitation, gets supernatant concentration to relative density 60-65 ℃ of survey 1.20, add 1 times of amount of water, stir, left standstill 8 hours, get supernatant concentration to the relative density 60-65 ℃ of thick paste of surveying 1.38-1.40;
5) get 1 part of thick paste, with 3 parts of sucrose, 1.25 parts in dextrin and ethanol are made granule, drying, granulate, packing.
Embodiment 2:
Take by weighing following raw materials according: Radix Ginseng 5g, Rhizoma Atractylodis Macrocephalae 5g, Fructus Corni 10g, Carapax et Plastrum Testudinis 10g, Carapax Trionycis 10g, Radix Scutellariae 3g, Poria 10g, Rhizoma Alismatis 25g, Radix Bupleuri 5g, Periostracum Cicadae 10g, Polyporus 10g, Ramulus Cinnamomi 1g, Semen Plantaginis 10g, Rhizoma Dioscoreae 15g, Ootheca Mantidis 25g; All the other are with embodiment 1.
Embodiment 3:
Take by weighing following raw materials according: Radix Ginseng 10g, Rhizoma Atractylodis Macrocephalae 10g, Fructus Corni 15g, Carapax et Plastrum Testudinis 15g, Carapax Trionycis 15g, Radix Scutellariae 9g, Poria 15g, Rhizoma Alismatis 30g, Radix Bupleuri 10g, Periostracum Cicadae 15g, Polyporus 15g, Ramulus Cinnamomi 5g, Semen Plantaginis 15g, Rhizoma Dioscoreae 20g, Ootheca Mantidis 30g; All the other are with embodiment 1.
Test example 1: medicine of the present invention is to the effect viewing test of mice basement membrane nephritis
One, material and method:
1. material:
Animal: large ear rabbit, male, 2-2.5Kg, the Beijing Medical University animal center provides; BALB/C mice, female, 18-22g, institute of biological products, Beijing animal center provides.
The medicine of medicine: embodiment 1 preparation.Rabbit igg: U.S. Miles company product.
2. method: the method that adopts rabbit igg accelerating type mice anti-basement membrane nephritis
2.1. nephrolytic sera preparation
With the Emulsion immunize rabbit that contains mice glomerular basement membrane and Freund's complete adjuvant, 1 time weekly, totally 6 times, getting rabbit anteserum is nephrolytic sera.
2.2. glomerulonephritis is made film and administration
Mice elder generation lumbar injection rabbit igg, the intravenous injection nephrolytic sera is made film again, evenly is divided into 5 groups according to the mouse retention protein level after 5 days.Model group: medicine 1.87g/Kg of the present invention, 3.75g/Kg (dose,equivalent); Cyclophosphamide (CY) 10mg/Kg lumbar injection, positive matched group.Other establishes the blank group.Every group 13-14,3 weeks of continuous oral administration.Survey urine protein, plasma albumin, blood urea nitrogen and cholesterol weekly.
Two, result:
See Table 1-4.
Made film (notes nephrolytic sera) back 5 days, mouse retention albumen plant all reach 300mg/dl or more than, model is set up.After the administration 7 days, mouse retention protein content, plasma albumin, cholesterol level all have clear improvement in basic, normal, high dosage group (except that low agent group cholesterol P value near 0.05, equal P＜0.05), similar to the CY group.After the administration 14 days, the urine protein of each dosage group still is better than model group, and other indexs also have in various degree to be improved, wherein high dose group plasma albumin, blood urea nitrogen, cholesterol] the low dose group cholesterol obviously is better than model group (P＜0.05).After 21 days, the urine protein of each dosage group and plasma urea nitrogen, high dose group cholesterol still obviously are better than model group, has certain dose-effect relationship, though each test group plasma albumin is a little more than model group, but all there has not been marked difference, this moment, the model group measured value gradually rose, and estimated that pathological changes has begun to recover.
Three, brief summary
1. medicine 1.87g/Kg of the present invention, 3.75g/Kg, oral urine protein, plasma urea nitrogen and the cholesterol of reducing of 7.5g/Kg, the rising plasma albumin has the obvious treatment effect to the mice anti-basement membrane nephritis.
2. medicine of the present invention has a certain amount of effect relationship to the therapeutical effect of chronic nephritis, and effect of high dosage is good, and is similar to cyclophosphamide 10mg/Kg lumbar injection action intensity, and 1.87g/Kg group (1/2 dose,equivalent) is slightly poor.
3. begun onset in the time of 7 days from administration, its curative effect can keep for 3 weeks at least.
The variation of protein content in table 1 urine (X ± SD)
| Group | Dosage (g/Kg) | Urine protein (mg/dl) | |||
| Before the medicine | Administration 7 days | Administration 14 days | Administration 21 days | ||
| Blank | 23±8(13) | 25.8±8(13) | 24±8(13) | 25±8(13) | |
| Model | 343±85(14) | 392±104(12) | 318±60(11) | 254±52(11) | |
| Cyclophosphamide | 0.01 | 346±88(13) | *308±67(12) | *265±47(10) | *180±63(10) |
| Medicine of the present invention | 1.87 | 346±88(13) | *292±73(12) | Δ275±40(12) | *212±38(12) |
| 3.75 | 343±85(14) | *307±62(14) | *261±63(14) | *200±58(13) | |
| 7.5 | 343±85(14) * | *277±101 (13) | *241±77(11) | **177±61(11) | |
Annotate: the t test:
*P＜0.05,
*P＜0.01, Δ P is near 0.05.
The variation of table 2 plasma albumin (X ± SD)
| Group | Dosage (g/Kg) | Albumin (g/L) | ||
| Administration 7 days | Administration 14 days | Administration 21 days | ||
| Blank | 33.9±0.9 | 33.7±1.5 | 32.9±2.1 | |
| Model | 20.5±2.0 | 23.5±3.3 | 25.1±2.2 | |
| Cyclophosphamide | 0.01 | *24.2±4.0 | Δ26.3±2.6 | 27.0±1.9 |
| Medicine of the present invention | 1.87 | **24.8±3.4 | 24.7±3.1 | 25.6±2.2 |
| 3.75 | *23.6±3.4 | 25.5±3.5 | 25.5±2.4 | |
| 7.5 | *24.8±5.2 | *28.1±4.4 | 26.9±2.8 | |
Annotate: the t test:
*P＜0.05,
*P＜0.01, Δ P is near 0.05.
The variation of table 3 plasma urea nitrogen (X ± SD)
| Group | Dosage (g/Kg) | Albumin (g/L) | ||
| Administration 7 days | Administration 14 days | Administration 21 days | ||
| Blank | 7.2±0.5 | 5.4±0.8 | 6.8±0.5 | |
| Model | 10.2±4.4 | 8.1±2.7 | 8.3±2.3 | |
| Cyclophosphamide | 0.01 | 9.9±5.6 | *5.4±2.0 | **5.4±0.6 |
| Medicine of the present invention | 1.87 | 8.1±3.5 | Δ6.2±1.7 | Δ6.5±1.7 |
| 3.75 | 7.4±2.3 | 6.9±1.3 | *6.7±0.6 | |
| 7.5 | 8.5±4.0 | *6.2±1.0 | *6.6±1.0 | |
Annotate: the t test:
*P＜0.05,
*P＜0.01, Δ P is near 0.05.
The variation of table 4 total plasma cholesterol (X ± SD)
| Group | Dosage (g/Kg) | Albumin (g/L) | ||
| Administration 7 days | Administration 14 days | Administration 21 days | ||
| Blank | 2.2±0.4 | 2.3±0.2 | 2.7±0.2 | |
| Model | 11.1±3.0 | 7.8±2.4 | 8.1±2.3 | |
| Cyclophosphamide | 0.01 | 9.1±2.2 | *5.8±1.0 | **4.6±1.0 |
| Medicine of the present invention | 1.87 | Δ8.8±2.6 | *5.6±1.8 | 7.3±1.9 |
| 3.75 | *8.2±2.4 | 6.1±1.8 | 6.5±1.6 | |
| 7.5 | **7.6±2.8 | *5.6±1.9 | *5.8±2.2 | |
Annotate: the t test:
*P＜0.05,
*P＜0.01, Δ P is near 0.05.
Experimental example 2: the clinical observation of treatment chronic nephritis
One, general clinical data
Diagnose and the typing standard according to the primary glomerulonephritis that Nanjing gastropathy meeting in 1985 is formulated, select Urology Department outpatient service of qualified Hebei Prov. Traditional Chinese Medicine Hospital and inpatient 30 examples as the object of observation, wherein male 17 examples, woman's 13 examples, age 7-62 year, 29.9 years old mean age, the shortest person of the course of disease 1 month, elder 3 years; The Chinese medical discrimination typing, spleen kidney qi deficiency of YIN person 20 examples, deficiency of spleen-YANG and kidneyYANG person 4 examples, hepatic and renal YIN deficiency person's 6 examples.
Two, Therapeutic Method
All case all adopts the Drug therapy of the embodiment of the invention 1 preparation, and each 1 bag, every day 3 times, 1 month is a course of treatment, forbidding other treatment medicine during the medication.
Three, observation index and statistical procedures
Observe the improvement situation of clinical symptoms and laboratory checking index before and after the treatment, laboratory checking index comprises 24 hours protein quantifications of urine, blood total protein, albumin, serum creatinine, blood urea nitrogen, routine blood test, immunoglobulin etc.T checked before and after statistical procedures adopted treatment.
Four, therapeutic outcome analysis
1. clinical curative effect analysis: the criterion of therapeutical effect in " the clinical research guideline of treatment by Chinese herbs chronic nephritis " formulated in 1987 according to State Administration of Traditional Chinese Medicine is judged curative effect.Alleviation person's 14 examples fully behind the 30 routine patient treatments, alleviation person's 8 examples substantially, 6 examples that take a turn for the better, 2 examples are invalid, and total effective rate is 93.3%.
2. the relation of clinical efficacy and traditional Chinese medical science typing sees Table 5.Medicine of the present invention is best to spleen kidney qi Yin bivacuity type curative effect, and is relatively poor to deficiency of spleen-YANG and kidneyYANG and liver-kidney yin deficiency effect.
Table 5
| Curative effect | Spleen kidney qi Yin bivacuity (20 example) | Deficiency of spleen-YANG and kidneyYANG (4 example) | The hepatic and renal YIN deficiency (6 example) |
| Alleviate fully | 13 | 1 | 0 |
| The basic alleviation | 5 | 1 | 2 |
| Take a turn for the better | 2 | 1 | 3 |
| Invalid | 0 | 1 | 1 |
3. to the improvement situation of laboratory checking index, see Table 6.By table 6 as seen, treatment back urine 24 hours albumen, serum creatinine, blood urea nitrogen obviously reduce, and have compared notable difference before the treatment, and blood albumin treatment back obviously raises, and compare before the treatment that there were significant differences.
Table 6
| Twenty-four-hour urine protein quantification (g/L) n=30 | Blood albumin (g/L) n=30 | Blood urea nitrogen (mmol/L) n=13 | Serum creatinine (μ mol/L) n=13 | |
| Before the treatment | 3.36±1.44 | 3.68±9.35 | 12.8±8.6 | 167.3±38.1 |
| After the treatment | 1.21±1.11 | 44.6±8.61 | 7.4±3.9 | 128.6±45.2 |
| The P value | ＜0.01 | ＜0.05 | ＜0.01 | ＜0.01 |
Claims (6)
1, a kind of medicine for the treatment of chronic nephritis, it is characterized in that it is made up of effective ingredient and/or acceptable accessories, wherein prepare raw materials of effective components and be: Radix Ginseng 5-10 weight portion, Rhizoma Atractylodis Macrocephalae 5-10 weight portion, Fructus Corni 10-15 weight portion, Carapax et Plastrum Testudinis 10-15 weight portion, Carapax Trionycis 10-15 weight portion, Radix Scutellariae 3-9 weight portion, Poria 10-15 weight portion, Rhizoma Alismatis 25-30 weight portion, Radix Bupleuri 5-10 weight portion, Periostracum Cicadae 10-15 weight portion, Polyporus 10-15 weight portion, Ramulus Cinnamomi 1-5 weight portion, Semen Plantaginis 10-15 weight portion, Rhizoma Dioscoreae 15-20 weight portion and Ootheca Mantidis 25-30 weight portion.
2, according to the described medicine of claim 1, wherein prepare the raw materials of effective components consumption and be: Radix Ginseng 9 weight portions, the Rhizoma Atractylodis Macrocephalae 9 weight portions, Fructus Corni 15 weight portions, Carapax et Plastrum Testudinis 15 weight portions, Carapax Trionycis 15 weight portions, Radix Scutellariae 6 weight portions, Poria 15 weight portions, Rhizoma Alismatis 30 weight portions, Radix Bupleuri 10 weight portions, Periostracum Cicadae 15 weight portions, Polyporus 15 weight portions, Ramulus Cinnamomi 3 weight portions, Semen Plantaginis 15 weight portions, Rhizoma Dioscoreae 20 weight portions and Ootheca Mantidis 30 weight portions.
3, according to claim 1 or 2 described medicines, it is electuary, granule, oral liquid, tablet or capsule.
4, according to the preparation method of any one described medicine in claim 1 or 2, it comprises and takes by weighing raw material, and Carapax Trionycis and Carapax et Plastrum Testudinis are decocted with water 2-3 time, and each 20-24 hour, collecting decoction filtered, and filtrate is left standstill; Radix Ginseng is decocted with water 2-3 time, and each 0.5-1.5 hour, collecting decoction filtered, and filtrate is left standstill; All the other medicines decoct with water 2-3 time, wherein Semen Plantaginis decocted a drug wrapped, and each 0.5-1.5 hour, merge decoction, filter, filtrate is left standstill; Merge above-mentioned three kinds of filtrates, filter, it is 90-95 ℃ of survey 1.08 that filtrate is concentrated into relative density, and room temperature to be chilled to adds equivalent ethanol and makes precipitation, get supernatant concentration to relative density 60-65 ℃ of survey 1.20, add water, stir, leave standstill, get supernatant concentration to the relative density 60-65 ℃ of thick paste of surveying 1.38-1.40 as effective ingredient, again thick paste is made electuary, granule, oral liquid, tablet or capsule.
5, according to the preparation method of the described medicine of claim 4, it comprises and takes by weighing raw material, and Carapax Trionycis and Carapax et Plastrum Testudinis are decocted with water 3 times, and each 24 hours, collecting decoction filtered, and filtrate is left standstill; Radix Ginseng is decocted with water twice, and each 1.5 hours, collecting decoction filtered, and filtrate is left standstill; All the other medicines decoct with water twice, wherein Semen Plantaginis are decocted a drug wrapped, and each 1.5 hours, merge decoction, filter, filtrate is left standstill; Merge above-mentioned three kinds of filtrates, filter, it is 90-95 ℃ of survey 1.08 that filtrate is concentrated into relative density, and room temperature to be chilled to adds equivalent ethanol and makes precipitation, get supernatant concentration to relative density 60-65 ℃ of survey 1.20, add 1 times of amount of water, stir, left standstill 8 hours, get supernatant concentration to the relative density 60-65 ℃ of thick paste of surveying 1.38-1.40 as effective ingredient, again thick paste is made electuary, granule, oral liquid, tablet or capsule.
6, according to the preparation method of the described medicine of claim 5, wherein will be as 1 part of the thick paste of effective ingredient, with 3 parts of sucrose, 1.25 parts in dextrin and ethanol are made granule, drying, granulate, packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410006354 CN1270750C (en) | 2004-02-27 | 2004-02-27 | Medicine for treating chronic nephritis, and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410006354 CN1270750C (en) | 2004-02-27 | 2004-02-27 | Medicine for treating chronic nephritis, and its prepn. method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1559468A CN1559468A (en) | 2005-01-05 |
| CN1270750C true CN1270750C (en) | 2006-08-23 |
Family
ID=34439761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410006354 Expired - Lifetime CN1270750C (en) | 2004-02-27 | 2004-02-27 | Medicine for treating chronic nephritis, and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1270750C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101204493B (en) * | 2007-12-19 | 2010-10-13 | 王青波 | Peroral Chinese traditional medicine composition for chronic nephritis |
| CN108186918B (en) * | 2018-01-30 | 2021-04-13 | 黑龙江中医药大学 | Traditional Chinese medicine composition for treating chronic glomerulonephritis and preparation method thereof |
-
2004
- 2004-02-27 CN CN 200410006354 patent/CN1270750C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1559468A (en) | 2005-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1836720A (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| CN1320896C (en) | Dangshen astragalus composition for regulating immunity and its preparation method | |
| CN1806834A (en) | Chinese medicine for treating AIDS | |
| CN1965951A (en) | Blood tonic capsule having ass hide and method for preparing same | |
| CN1539458A (en) | Chinese materia medica preparation made from gen-seng and astragalus root for strengthening the body resistance and anti cancer as well as producing method | |
| CN1270750C (en) | Medicine for treating chronic nephritis, and its prepn. method | |
| CN1052889C (en) | Chinese proprietary for curing hepatitis | |
| CN1269509C (en) | Medicine for treating chronic nephritis, and its prepn. method | |
| CN1108159C (en) | Traditional Chinese medicine for curing diabetes and kidney deficiency | |
| CN1294980C (en) | Medicine for treating liver disease | |
| CN1973850A (en) | Medicine composition for treating allergic rhinitis and its prepn process | |
| CN1579523A (en) | Infant's Runtu granulars and preparation method | |
| CN1903347A (en) | Medicine composition for treating alimentary canal diseases, prepn. method and application thereof | |
| CN1230194C (en) | Medicine for preventing and treating deficiency-cold and its preparation | |
| CN1076622C (en) | Chinese medicine for curing nephritis | |
| CN116726083B (en) | Traditional Chinese medicine composition for treating chronic prostatitis | |
| CN1128634C (en) | Hepatitis B recuperating medicine granule | |
| CN1042495C (en) | Medicine for benefitting Qi, removing cancer and raising leucocyte and its prepn. | |
| CN1666763A (en) | Dripping pills of six Ingredients with Rehmanniae | |
| CN1823945A (en) | Chinese medicinal preparation for treating fatly liver and its preparation method | |
| CN1785358A (en) | Medicine for treating acne and its preparation method | |
| CN1050297C (en) | Chinese herbal medicine composition for preparing non-dependence anti-cancer pain-alleviating drug and preparation thereof | |
| CN1202856C (en) | Medicine for treating AIDS and its preparation method | |
| CN1256083C (en) | Medicine for boosting qi and nourishing blood and its prepatation method | |
| CN1189207C (en) | Chinese medicinal composition for improving human immunity and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: ZHUHAI ANSHENG FENGHUANG PHARMACEUTICAL Co.,Ltd. Assignor: Li Guocheng Contract fulfillment period: 2007.1.1 to 2012.1.1 Contract record no.: 2009440001628 Denomination of invention: Medicine for treating chronic nephritis and its preparing process Granted publication date: 20060823 License type: Exclusive license Record date: 20091021 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2007.1.1 TO 2012.1.1; CHANGE OF CONTRACT Name of requester: ZHUHAI ANSHENG FENGHUANG PHARMACY CO., LTD. Effective date: 20091021 |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060823 |
|
| CX01 | Expiry of patent term |